摘要目的 探讨达格列净片对糖尿病患者血糖、胰岛素抵抗及基质金属蛋白酶-2（MMP-2）的影响。方法 选取2020年10月至2021年10月福建省立医院的200例糖尿病患者作为研究对象，采用随机数字表法将其分为对照组和观察组，每组各100例。对照组患者给予二甲双胍治疗，观察组患者给予达格列净片治疗。比较两组患者的总有效率、空腹血糖（FBG）、餐后2 h血糖（2 h PG）、空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）、MMP-2含量。结果 观察组患者的总有效率（90.00%）高于对照组（65.00%），差异有统计学意义（P＜0.05）；治疗前，两组患者的FBG、2 h PG、FINS、HOMA-IR、MMP-2含量比较，差异无统计学意义（P＞0.05）。两组患者治疗后的FBG、2 h PG、FINS、HOMA-IR、MMP-2含量低于治疗前，且观察组患者治疗后的FBG、2 h PG、FINS、HOMA-IR、MMP-2含量低于对照组，差异有统计学意义（P＜0.05）。结论 达格列净片可有效降低糖尿病患者的血糖，同时能够有效改善胰岛素抵抗，并抑制MMP-2水平，疗效显著。
Abstract：Objective To investigate the effect of Dapagliflozin Tablets on blood glucose, insulin resistance and matrix metalloproteinase-2 (MMP-2) in diabetic patients. Methods A total of 200 diabetic patients from Fujian Provincial Hospital from October 2020 to October 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 100 patients in each group. The control group was treated with Metformin, and the observation group was treated with Dapagliflozin Tablets. The total effective rate, fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h PG), fasting insulin (FINS), insulin resistance index (HOMA-IR) and MMP-2 contents were compared between the two groups. Results The total effective rate in observation group (90.00%) was higher than that in control group (65.00%), and the difference was significant (P＜0.05). Before treatment, there were no significant differences in FBG, 2 h PG, FINS, HOMA-IR and MMP-2 content between the two groups (P＞0.05). The FBG, 2 h PG, FINS, HOMA-IR and MMP-2 content in the two groups after treatment were lower than those before treatment, and the FBG, 2 h PG, FINS, HOMA-IR and MMP-2 content in the observation group after treatment were lower than those in the control group, and the differences were statistically significant (P＜0.05). Con-clusion Dapagliflozin Tablets can effectively reduce blood glucose in diabetic patients, and has a significant effect on improving insulin resistance and inhibiting MMP-2 level.
京公网安备 11010502046607号